BlinkLab raises $17.5m to fund FDA autism diagnostic trial and ADHD expansion

Perth-based digital diagnostics company BlinkLab (ASX: BB1) has raised $17.5 million through an oversubscribed placement to fund a pivotal US Food and Drug Administration (FDA) validation study for its smartphone-based autism diagnostic aid, expand into ADHD diagnostics and pursue European…


Click here to view the original article.